Total buying$1.84M10 buys
INBX
Inhibrx Biosciences, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 09/24 to 10/24.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$00 sells
Net open-market+$1.84MBuying minus selling
Active insiders1Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 14, 2026
Open-market transaction mix · 10 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 4 | 0 | 0 | $998k | $0 | $998k |
| Oct 2026 | 6 | 0 | 0 | $848k | $0 | $848k |
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (1)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- LM+$1.8M
INBX transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $8.57kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $208kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $205kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $8.57kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $209kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $207kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $305kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $148kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $216kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Lappe MarkCEO | P · buySEC filing ↗ | $328kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period10transactionstxns
- P · Open-market buys · dominant10 · 100%
Activity by reported role
A joint filing can contribute to multiple rolesChief executive officer10
Reported Holdings After
Separated by insider, security, and ownership type
Lappe MarkCommon Stock · Indirect · By the Lappe Family Trust
745,588Oct 14, 2026
Lappe MarkCommon Stock · Indirect · By Lappe Descendants' Trust
170,000Oct 14, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 24 → Oct 24
LessMore
Inhibrx Biosciences, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Inhibrx Biosciences, Inc.?
Lappe Mark.
When was the latest reported open-market purchase?
Lappe Mark reported a buy on Oct 14, 2026 valued at $8.57k. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $1,847,760.52. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.